Several inhibitors (rapamycin analogs) targeting the PI3K/AKT/mTOR pathway have been investigated to counteract the mechanism by which PTEN deletion promotes prostate cancer progression (60), but their antitumor effects have been disappointing. This evidence concerns the gene AKT1 and prostate cancer.